Further studies of pharmacological interventions targeting RORα-mediated mitochondria quality control may provide therapeutic strategies against NASH as well as other diseases associated with defects in mitochondrial function. This evidence concerns the gene RORA and metabolic dysfunction-associated steatohepatitis.